Effect of Sativex on spasticity-associated symptoms in patients with multiple sclerosis

Expert Rev Neurother. 2015;15(8):909-18. doi: 10.1586/14737175.2015.1067607. Epub 2015 Jul 11.


Individuals with multiple sclerosis (MS) spasticity may experience a range of symptoms, such as bladder dysfunction, pain, impaired sleep quality and mobility restrictions that worsen as spasticity severity increases. In this review, the effects of Sativex(®) oromucosal spray on symptoms and functional impairment associated with MS-related spasticity were examined. Across Sativex studies, there was a clear trend for improvement in spasticity-associated symptoms that was more pronounced and sustained over time in Sativex responders. Meaningful symptomatic improvement was achieved within the recommended dosage limit of ≤12 sprays per day. In appropriate patients, Sativex has the potential to minimize the consequences of spasticity-related symptoms on quality of life and reduce the economic burden on healthcare systems.

Keywords: Sativex; multiple sclerosis; review; spasticity; symptom management.

Publication types

  • Review

MeSH terms

  • Cannabidiol
  • Cannabinoids / therapeutic use*
  • Dronabinol
  • Drug Combinations
  • Humans
  • Multiple Sclerosis / complications*
  • Muscle Spasticity / drug therapy*
  • Muscle Spasticity / etiology*
  • Plant Extracts / therapeutic use*
  • Sleep / drug effects
  • Visual Analog Scale


  • Cannabinoids
  • Drug Combinations
  • Plant Extracts
  • Cannabidiol
  • Dronabinol
  • nabiximols